Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 18, 2004. The report primarily details corporate actions regarding share buybacks, employee trust transactions, and changes in directors' interests in the company's Ordinary Shares and American Depository Shares (ADS).
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transaction prices:
- Share Buyback Price: 1070.50p per ordinary share.
- Employee Trust ADS Purchase Price: $40.23456 per ADS.
- Scientific Advisory Board ADS Purchase Price: $40.020 per ADS.
Material Changes and Corporate Actions
The following material transactions occurred during the reporting period:
- Share Repurchase: On March 17, 2004, the company purchased 450,000 ordinary shares for cancellation at 1070.50p per share, utilizing authority granted at the May 19, 2003 Annual General Meeting.
- Employee Trust Transactions:
- On March 15, 2004, the GSK Trust purchased 368 ADS for the Performance Share Plan and subsequently transferred them to participants.
- On March 17, 2004, the GSK Trust transferred 4,382 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Interests:
- Dr. L. Shapiro: 323 ADS were purchased on March 16, 2004, under the Scientific Advisory Board Share Allocation Plan.
- Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe hold interests in shares held by the GSK Trust as potential beneficiaries.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a report of regulatory disclosures regarding share ownership and corporate actions.
Key Facts for Investor Verification
- Verify the total number of shares repurchased for cancellation (450,000) against the company's authorized buyback limit.
- Confirm the impact of the share buyback on the company's total share count and earnings per share.
- Review the specific terms of the GlaxoSmithKline Performance Share Plan and the SmithKline Beecham Employee Share Option Plan 1991 regarding the transferred shares.
- Check subsequent filings for any further changes in the interests of directors Dr. J-P Garnier, Dr. T Yamada, Mr. J D Coombe, and Dr. L Shapiro.